OA12293A - 3-Azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity. - Google Patents

3-Azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity. Download PDF

Info

Publication number
OA12293A
OA12293A OA1200200386A OA1200200386A OA12293A OA 12293 A OA12293 A OA 12293A OA 1200200386 A OA1200200386 A OA 1200200386A OA 1200200386 A OA1200200386 A OA 1200200386A OA 12293 A OA12293 A OA 12293A
Authority
OA
OAPI
Prior art keywords
alkyl
aryl
halogen
optionally substituted
substituted
Prior art date
Application number
OA1200200386A
Other languages
English (en)
Inventor
Bernard Joseph Banks
Douglas James Critcher
Ashley Edward Fenwick
David Morris Gethin
Stephen Paul Gibson
Graham Lunn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA12293A publication Critical patent/OA12293A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA1200200386A 2000-06-23 2001-06-07 3-Azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity. OA12293A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0015562.2A GB0015562D0 (en) 2000-06-23 2000-06-23 Heterocycles

Publications (1)

Publication Number Publication Date
OA12293A true OA12293A (en) 2004-03-18

Family

ID=9894368

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200386A OA12293A (en) 2000-06-23 2001-06-07 3-Azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity.

Country Status (34)

Country Link
EP (1) EP1292574A1 (fr)
JP (1) JP2004512263A (fr)
KR (1) KR20040002386A (fr)
CN (1) CN1639121A (fr)
AP (1) AP2002002698A0 (fr)
AR (1) AR028969A1 (fr)
AU (1) AU781837B2 (fr)
BG (1) BG107329A (fr)
BR (1) BR0111867A (fr)
CA (1) CA2412188A1 (fr)
CZ (1) CZ20023967A3 (fr)
DO (1) DOP2001000187A (fr)
DZ (1) DZ3368A1 (fr)
EA (1) EA005117B1 (fr)
GB (1) GB0015562D0 (fr)
HR (1) HRP20020998A2 (fr)
HU (1) HUP0301228A3 (fr)
IL (1) IL153427A0 (fr)
IS (1) IS6637A (fr)
MA (1) MA26915A1 (fr)
MX (1) MXPA02012878A (fr)
NO (1) NO20026168L (fr)
NZ (1) NZ523141A (fr)
OA (1) OA12293A (fr)
PA (1) PA8519401A1 (fr)
PE (1) PE20020253A1 (fr)
PL (1) PL365956A1 (fr)
SK (1) SK17172002A3 (fr)
TN (1) TNSN01094A1 (fr)
UA (1) UA73176C2 (fr)
UY (1) UY26787A1 (fr)
WO (1) WO2001098267A1 (fr)
YU (1) YU91802A (fr)
ZA (1) ZA200210278B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60226161T2 (de) * 2001-10-22 2009-07-02 Pfizer Products Inc., Groton 3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren
KR101108014B1 (ko) * 2002-05-17 2012-01-25 티오가 파마슈티칼스, 인코포레이티드 선택성 아편제 수용체 조절인자로서 효과적인 화합물의 용도
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
SI1745040T1 (sl) 2004-02-23 2010-04-30 Venue Glaxo Group Ltd Derivati azabiciklo(3.1.0)heksana, uporabni kot modulatorji dopaminskih receptorjev d3
GB0507680D0 (en) 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
EP1891056B1 (fr) 2005-06-14 2010-10-13 Glaxo Group Limited Nouveaux composés
DE602007012531D1 (de) * 2006-04-03 2011-03-31 Glaxo Group Ltd Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
WO2008121496A1 (fr) 2007-03-30 2008-10-09 Tioga Pharmaceuticals Inc. Agonistes du récepteur opiacé kappa pour le traitement du syndrome du côlon irritable avec alternance ou à diarrhée prédominante
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
AU2011263417B2 (en) 2010-06-11 2014-03-27 Rhodes Technologies Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof
WO2012042539A2 (fr) 2010-09-28 2012-04-05 Panacea Biotec Ltd Nouveaux composés bicycliques
US9663463B2 (en) * 2013-11-20 2017-05-30 Sanwa Kagaku Kenkyusho Co., Ltd. 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose
RU2017144548A (ru) 2015-05-20 2019-06-20 Санва Кагаку Кенкюсо Ко., Лтд. Кристаллическая соль нового производного 3-азабицикло[3.1.0]гексана и ее применение в медицине
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
KR20190129867A (ko) * 2017-02-17 2019-11-20 트레베나, 인코포레이티드. 5-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
CA3054122A1 (fr) 2017-03-02 2018-09-07 Sanwa Kagaku Kenkyusho Co., Ltd. Agent therapeutique pour troubles lies a la consommation d'alcool
CN108250088B (zh) * 2018-01-04 2020-10-30 四川之江高新材料股份有限公司 N，n，n′-三甲基-n′-羟乙基双氨基乙基醚的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065230A (en) * 1959-03-16 1962-11-20 Burroughs Wellcome Co Azabicyclohexanes and method of preparing them
IL86061A (en) * 1987-04-16 1992-07-15 Lilly Co Eli Derivatives of trans-3,4-isomer of 4-methyl-4-phenyl-piperidines,process for their preparation and pharmaceutical compositions containing them
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5

Also Published As

Publication number Publication date
AU6259101A (en) 2002-01-02
IL153427A0 (en) 2003-07-06
BG107329A (en) 2003-07-31
NO20026168L (no) 2003-02-18
HRP20020998A2 (en) 2004-02-29
PL365956A1 (en) 2005-01-24
AP2002002698A0 (en) 2002-12-31
BR0111867A (pt) 2003-07-01
UA73176C2 (en) 2005-06-15
GB0015562D0 (en) 2000-08-16
SK17172002A3 (sk) 2004-09-08
MA26915A1 (fr) 2004-12-20
EP1292574A1 (fr) 2003-03-19
IS6637A (is) 2002-11-28
TNSN01094A1 (fr) 2005-11-10
YU91802A (sh) 2006-05-25
NZ523141A (en) 2005-06-24
ZA200210278B (en) 2003-12-19
PA8519401A1 (es) 2002-12-30
HUP0301228A3 (en) 2005-08-29
KR20040002386A (ko) 2004-01-07
DOP2001000187A (es) 2002-03-30
CN1639121A (zh) 2005-07-13
DZ3368A1 (fr) 2001-12-27
CZ20023967A3 (cs) 2004-02-18
AR028969A1 (es) 2003-05-28
MXPA02012878A (es) 2003-05-14
HUP0301228A2 (hu) 2003-08-28
WO2001098267A1 (fr) 2001-12-27
JP2004512263A (ja) 2004-04-22
EA005117B1 (ru) 2004-10-28
CA2412188A1 (fr) 2001-12-27
PE20020253A1 (es) 2002-04-08
UY26787A1 (es) 2002-01-31
AU781837B2 (en) 2005-06-16
EA200201269A1 (ru) 2003-06-26
WO2001098267A8 (fr) 2003-02-27
NO20026168D0 (no) 2002-12-20

Similar Documents

Publication Publication Date Title
CA2356300C (fr) Derives 3-azabicyclo[3.1.0]hexane utiles en therapie
OA12293A (en) 3-Azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity.
JP2840448B2 (ja) インドール誘導体
JP2002504483A (ja) ヒスタミンｈ３受容体リガンド
WO2012155199A1 (fr) Dérivés d'amine agissant comme bloqueurs du canal potassium
AU2003276201A1 (en) Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
JP6434528B2 (ja) 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用
CA2794176C (fr) Nouveaux derives de benzamide
JP2005504800A (ja) ピリミジノン化合物及びその薬剤として許容される塩の製造方法
US20020025948A1 (en) 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
KR101800594B1 (ko) 미량 아민 결합 수용체(taar) 조절제로서 6-아미노-5,6,7,8-테트라하이드로나프탈렌-2-일 또는 3-아미노크로만-7-일 유도체
US20030207876A1 (en) 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
CA2287394A1 (fr) Methodes de synthese d'imidazoles 2-substitues
CA1294274C (fr) Methode de traitement de la tension musculaire, de la spasticite musculaire et de l'anxiete a l'aide de 3-aryloxy-azetidinecarboxamides
CA2758367A1 (fr) Derives de n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique
CA2751866A1 (fr) Derives de n-[(6-aza-bicyclo[3.2.1]oct-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique
CA2751863A1 (fr) Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique
KR20170045941A (ko) 1,2,3-트리아졸 유도체 화합물, 이의 제조방법 및 이를 포함하는 당뇨병 치료용 조성물
CA2755526A1 (fr) Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique